Jonathan J. Havel
- Oncology top 1%
- Cancer Immunotherapy and Biomarkers 6
- CAR-T cell therapy research 2
- Peptidase Inhibition and Analysis 2
- Immunology top 2%
- Immunotherapy and Immune Responses 5
- T-cell and B-cell Immunology 2
- Immune Cell Function and Interaction 2
- Otorhinolaryngology top 2%
- Cancer Research top 5%
-
- Ubiquitin and proteasome pathways 2
-
- Hippo pathway signaling and YAP/TAZ 2
- Co-authors
- Timothy A. ChanDiego ChowellAlexis DesrichardNadeem RiazLuc G.T. MorrisRajarsi MandalYasin ŞenbabaoğluA. Ari Hakimi
- Partner nations
- United StatesChinaJapan
In The Last Decade
Jonathan J. Havel
14 papers receiving 2.7k citations
Hit Papers
Peers
Comparison fields: 5 of 97
- Oncology 1.9k
- Immunology 1.1k
- Otorhinolaryngology 144
- Cancer Research 493
- Pulmonary and Respiratory Medicine 683
Countries citing papers authored by Jonathan J. Havel
This map shows the geographic impact of Jonathan J. Havel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan J. Havel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan J. Havel more than expected).
Fields of papers citing papers by Jonathan J. Havel
This network shows the impact of papers produced by Jonathan J. Havel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan J. Havel. The network helps show where Jonathan J. Havel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jonathan J. Havel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 13 | |
| 2 | 2020 | 125 | |
| 3 | The evolving landscape of biomarkers for checkpoint inhibitor immunotherapybreakdown → | 2019 | 1591 |
| 4 | 2017 | 31 | |
| 5 | 2017 | 15 | |
| 6 | 2017 | 21 | |
| 7 | 2016 | 101 | |
| 8 | The head and neck cancer immune landscape and its immunotherapeutic implicationsbreakdown → | 2016 | 551 |
| 9 | 2016 | 125 | |
| 10 | 2015 | 26 | |
| 11 | 2015 | 3 | |
| 12 | 2014 | 48 | |
| 13 | 2012 | 23 | |
| 14 | 2008 | 35 |
About Jonathan J. Havel
Jonathan J. Havel is a scholar working on Oncology, Immunology and Immunology and Allergy, having authored 14 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (6 papers), Immunotherapy and Immune Responses (5 papers), CAR-T cell therapy research (2 papers), Peptidase Inhibition and Analysis (2 papers), Ubiquitin and proteasome pathways (2 papers), Hippo pathway signaling and YAP/TAZ (2 papers), T-cell and B-cell Immunology (2 papers) and Immune Cell Function and Interaction (2 papers). The work is most often cited by research in Oncology (1.9k citations), Immunology (1.1k citations) and Otorhinolaryngology (144 citations). Jonathan J. Havel has collaborated with scholars based in United States, China and Japan. Frequent co-authors include Timothy A. Chan, Diego Chowell, Alexis Desrichard, Nadeem Riaz, Luc G.T. Morris, Rajarsi Mandal, Yasin Şenbabaoğlu, A. Ari Hakimi, Ken-Wing Lee and Ian Ganly. Their work appears in journals such as Nature Genetics, Nature reviews. Cancer and Oncogene.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.